Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 6/20 | 0.52 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.51 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15341829 | 0.85 | CYP19A1 (0.50) | KEAP1HCAR3SLC9A1POLBMAPT | |
| SCHEMBL16831706 | 0.82 | HCAR3 (0.60) | KEAP1HCAR3HPGDPOLBMAPT | |
| SCHEMBL3285240 | 0.81 | PKM (0.53) | KEAP1HCAR3HPGDPOLBALDH1A1 | |
| SCHEMBL19236877 | 0.80 | KEAP1 (0.49) | KEAP1HCAR3SLC9A1HPGDPOLB | |
| SCHEMBL24296719 | 0.80 | PARP15 (0.39) | KEAP1HCAR3HPGDMAPTSMN1; SMN2 | |
| SCHEMBL14200034 | 0.80 | HCAR3 (0.58) | KEAP1HCAR3HPGDMAPTSMN1; SMN2 | |
| SCHEMBL24296700 | 0.80 | PARP15 (0.39) | KEAP1HCAR3HPGDMAPTSMN1; SMN2 | |
| SCHEMBL15341912 | 0.79 | TDO2 (0.45) | KEAP1HCAR3SLC9A1HPGDPOLB | |
| SCHEMBL19619606 | 0.78 | KEAP1 (0.40) | KEAP1HCAR3SLC9A1HPGDPOLB | |
| SCHEMBL21169561 | 0.77 | HCAR3 (0.55) | HCAR3SLC9A1POLBMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | PROMEGA CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | PROMEGA CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-11572367-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20160130275-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160108046-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9238039-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140154240-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-8436016-B2 | Fused heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. | 2013-05-07 | — | — | US | disclosed |
| US-20110201607-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck, Sharp & Dohme, Corp. | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140154240-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | KEAP1 3964/4885HCAR3 3960/4885SLC9A1 1895/4885 |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | CYP4Z1, CYP2E1, CYP2F1 | KEAP1 1432/4885HCAR3 4539/4885SLC9A1 4599/4885 |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | KEAP1 2451/4885HCAR3 205/4885SLC9A1 4160/4885 |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | KEAP1 3964/4885HCAR3 3960/4885SLC9A1 1895/4885 |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | KEAP1 399/4885HCAR3 4732/4885SLC9A1 4817/4885 |
| US-20110201607-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | KEAP1 2960/4885HCAR3 227/4885SLC9A1 3152/4885 |
| US-20160130275-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | KEAP1 3964/4885HCAR3 3960/4885SLC9A1 1895/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | KEAP1 818/4885HCAR3 4019/4885SLC9A1 2618/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | KEAP1 818/4885HCAR3 4019/4885SLC9A1 2618/4885 |
| US-20160108046-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KEAP1 251/4885HCAR3 1898/4885SLC9A1 3735/4885 |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | KEAP1 3109/4885HCAR3 2016/4885SLC9A1 3748/4885 |
| US-11572367-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | KEAP1 766/4885HCAR3 118/4885SLC9A1 1247/4885 |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | KEAP1 766/4885HCAR3 118/4885SLC9A1 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.